CG Oncology to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
CG Oncology (NASDAQ: CGON), a late-stage clinical biopharmaceutical company, has announced its participation in the Morgan Stanley 22nd Annual Global Healthcare Conference. Arthur Kuan, the company's Chairman & CEO, is scheduled for a fireside chat on September 6, 2024, at 10:45 am ET in New York, NY.
CG Oncology focuses on developing a potential backbone bladder-sparing therapeutic for bladder cancer patients. Interested parties can access the live audio webcast of the presentation from the Investor Relations section of the company's website at www.cgoncology.com. A replay of the webcast will be available for approximately 90 days after the live presentation concludes.
Details
News Market Reaction – CGON
The recorded move for CGON in the trading session of this news was +0.55%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
IRVINE, Calif., Aug. 30, 2024 (GLOBE NEWSWIRE) -- CG Oncology, Inc. (NASDAQ: CGON), a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients with bladder cancer, today announced that Arthur Kuan, Chairman & Chief Executive Officer, is scheduled to participate in a fireside chat on Friday, September 6, 2024, at 10:45 am ET, in New York, NY.
Interested parties can access the live audio webcast for this conference from the Investor Relations section of the company's website at www.cgoncology.com. The webcast replay will be available after the conclusion of the live presentation for approximately 90 days.
About CG Oncology
CG Oncology is a late-stage clinical biopharmaceutical company focused on developing and commercializing a potential backbone bladder-sparing therapeutic for patients afflicted with bladder cancer. CG Oncology sees a world where urologic cancer patients may benefit from our innovative immunotherapies to live with dignity and have an enhanced quality of life. To learn more, please visit: www.cgoncology.com.
Contacts
Media
Sarah Connors
VP, Communications and Patient Advocacy
(508) 654-2277
sarah.connors@cgoncology.com
Investor Relations
Laurence Watts
New Street IR
(619) 916-7620
IR@cgoncology.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.